Literature DB >> 14575472

Synthesis and evaluation of macrocyclic transition state analogue inhibitors for alpha-chymotrypsin.

Kristina K Hansen1, Benjamin Grosch, Sorana Greiveldinger-Poenaru, Paul A Bartlett.   

Abstract

Lactams 1 and 2 are readily formed from acyclic precursors in the presence of trypsin and chymotrypsin, respectively, identifying the macrocyclic ring system as a potential motif for constrained transition state analogue inhibitors of the serine peptidases. Ketone 3 was synthesized and shown to be a modest inhibitor of chymotrypsin (Ki = 220 microM), albeit 4-fold more potent than the acyclic hydroxy acid 25 (Ki = 1.5 mM as a mixture of epimers). A precursor (31) to the amino boronic acid 4 was also prepared; although this derivative was a potent inhibitor of chymotrypsin (Ki = 130 nM) by virtue of the boronic acid moiety, it showed no advantage over the des-amino analogue 32 (Ki = 120 nM), which is not capable of cyclizing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575472     DOI: 10.1021/jo034837z

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  3 in total

1.  Engineering strategy to improve peptide analogs: from structure-based computational design to tumor homing.

Authors:  David Zanuy; Francisco J Sayago; Guillem Revilla-López; Gema Ballano; Lilach Agemy; Venkata Ramana Kotamraju; Ana I Jiménez; Carlos Cativiela; Ruth Nussinov; April M Sawvel; Galen Stucky; Erkki Ruoslahti; Carlos Alemán
Journal:  J Comput Aided Mol Des       Date:  2012-12-14       Impact factor: 3.686

2.  Serine protease inhibition by a silanediol peptidomimetic.

Authors:  Swapnil Singh; Scott McN Sieburth
Journal:  Org Lett       Date:  2012-08-16       Impact factor: 6.005

3.  Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors.

Authors:  Maya B Kostova; D Marc Rosen; Ying Chen; Ronnie C Mease; Samuel R Denmeade
Journal:  J Med Chem       Date:  2013-06-04       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.